Arena Pharmaceuticals' new obesity drug Belviq hits the U.S. shelves today. Lonnel Coats, Eisai CEO, and Jack Lief, Arena CEO, discuss expectations for the drug.» Read More
*Novo shares up 0.7 percent, outperforming sector. COPENHAGEN, May 24- Danish drug maker Novo Nordisk said it could launch obesity treatment liraglutide in the United States by the end of next year and rejected some analysts' doubts over the medicine's commercial potential.
NEW YORK, May 9- Three long-time favorites of the short-selling crowd are making those investors eat crow, as Tesla, Barnes& Noble and Green Mountain Coffee are racking up big gains, making an already painful year for contrarian investors even worse. Barnes& Noble shares rose 24 percent on reports of a possible acquisition of some of its assets by Microsoft.
Feb 21- European health regulators for a second time rejected a diet pill developed by Vivus Inc and said the obesity treatment would not be approved there unless the company conducts a large lengthy trial to prove its heart safety, Vivus said on Thursday.
It was sold legally before the U.S. Food and Drug Administration gained the power to regulate drugs in 1938.. It was widely used to treat weight-loss during World War Two and afterwards, but was eventually banned as an obesity medication by the FDA in 1979..
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
Jan 22- Arena Pharmaceuticals Inc said the European health regulator had raised concerns with the company's obesity drug, Belviq, sending its shares down as much as 10 percent.
TheStreet.com offers up 13 biotech predictions for 2013.
As Christmas overeating gives way to under-fulfilled new year diets, the pharmaceutical industry's appetite has been whetted for a fresh surge in business.
Here's how to profit from the coming Alexza FDA run down.